Featured Resource

Clinical Development
Brochure

The Clinical Development Brochure provides a detailed overview of the oncology clinical trials, therapeutic targets, and molecules in our pipeline.

Clinical Development Program Brochure
Information on each of the molecules that Lilly has in clinical development can be found here.

BTK Inhibitor

Pirtobrutinib

CDK4/6 Inhibitor

Abemaciclib

FGFR3 Inhibitor

LOXO-435

FRα Antibody-Drug Conjugate

LY4170156

KRAS G12C Inhibitor

Olomorasib

Nectin-4 Antibody-Drug Conjugate 1

LY4101174

Nectin-4 Antibody-Drug Conjugate 2

LY4052031

Prostate-Specific Membrane Antigen (PSMA)

[Ac-225]-PSMA-62

RET Inhibitor

Selpercatinib

Selective Estrogen Receptor Degrader

Imlunestrant

SMARCA2 (BRM) Inhibitor

LY4050784

VEGF Receptor-2 Antagonist

Ramucirumab

For information on trial enrollment, locations, and more, call 1-800-545-5979.